FOR2240-Logo2FOR2240-Logo2FOR2240-Logo2FOR2240-Logo2
  • Home
  • About
  • Projects
    • P1 Lymph-Transplant
    • P2 Modulators of LA
    • N1 Ocular GvHD
    • N2 ABCB5 & Pterygium
    • P4 Ocular Melanoma
    • P5 Myeloid Cells
    • P6 Microglia in AMD
    • P8 Uveitis
    • C1 Eye Imaging
    • C2 Management
  • Team
    • Executive Board
    • Research Groups
    • Central Projects
    • Associated projects
    • Alumni
  • Publications
  • Links
  • Events
    • Guest lectures
    • Retreats
    • Symposium
  • News
✕

Funding for glaucoma stent study

The Initiator Initiated Trial (IIT) entitled “Comparison of Positioning, Schlemm Canal Dilation and Intraocular Pressure after Hydrus Microstent vs. I Stent Injection in Combination with Cataract Surgery” conducted by the Center for Ophthalmology at the University Hospital of Cologne under the leadership of Univ.-Prof. Dr. Verena Prokosch has been approved by the Alcon Global Grant Committee and will be funded with approximately 84,500 Euros.

The goal of this Inititator Initiated Trial is to compare for the first time the positioning and pressure reduction of two different novel glaucoma stents. Both stents are considered minimally invasive glaucoma surgery procedures for lowering pressure to help patients with the common disease glaucoma – about 2 percent of the population. The Center for Ophthalmology in Cologne was the first university hospital in Germany to introduce the Hydrus 2021 as a treatment option.

Related posts

Augenklinik, Gast Professor Yakefumi Yamaguchi, Professor Claus Cursifen

September 19, 2023

International guest from Japan


Read more
Claus Cursiefen
July 31, 2023

Academia Ophthalmologica Internationalis: Prof. Cursiefen new member


Read more

Quelle MedizinFoto UniKlinik Köln

July 31, 2023

National top ranking for ophthalmology


Read more

News

  • International guest from Japan
  • Academia Ophthalmologica Internationalis: Prof. Cursiefen new member
  • National top ranking for ophthalmology
  • Funding for glaucoma stent study
  • The aging eye

More information

  • Publication highlights
  • Jobs
  • Contact
  • Impressum
  • Datenschutz

Newest publications

Supplemental Anti Vegf A-Therapy Prevents Rebound…(2020)


Bevacizumab Induces Upregulation of Keratin 3 and VEGFA in Human…(2020)


Immune reactions after modern lamellar (DALK, DSAEK, DMEK) versus conventional…(2020)


Contact

Claudia Bock
Management Office
DFG Research Unit FOR2240
Department of Ophthalmology
University of Cologne
Kerpener Str. 62
50937 Cologne, Germany

www.for2240.de

Tel. +49 (0)221 478 32845
Fax. +49 (0)221 478 5094
claudia.bock@uk-koeln.de

Partnerlogos

© 2021 FOR2240 | Online Marketing von Resulted Lübeck